All In Biotech

NDA 020988 · Wyeth Pharms

Protonix Iv

Pantoprazole Sodium · Intravenous

Last checked: Nov 20, 2026Latest source record: Aug 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Mar 22, 2001

Approved uses

5

Original approval plus efficacy supplements

Registered trials

231

49 Phase 3, 17 recruiting

FAERS reports

150,017

116,373 serious, 16,700 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 6, 2026.

PROTONIX I.V. is indicated for treatment of: • gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults and up to 7 days in pediatric patients 3 months and older. • pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults. Limitations of Use The safety and effectiveness of PROTONIX I.V. for the treatment of upper gastrointestinal bleeding have not been established in adult or pediatric patients. PROTONIX I.V. is a proton pump inhibitor (PPI) indicated for treatment of: • gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults and up to 7 days in pediatric patients 3 months and older. ( 1 ) • pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome in adults. ( 1 ) Limitations of Use The safety and effectiveness of PROTONIX I.V. for the treatment of upper gastrointestinal bleeding have not been established in adult or pediatric patients. ( 1 )

Mechanism: Pantoprazole is a PPI that suppresses the final step in gastric acid production by covalently binding to the (H + , K + )-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the (H + , K + )-ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested (20 mg to 120 mg).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PROTONIX IV · PANTOPRAZOLE SODIUM EQ 40MG BASE/VIAL · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Pantoprazole" as an intervention, any sponsor and status, largest first.

All 231 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease24,473
  • acute kidney injury13,898
  • fatigue11,670
  • renal failure10,884
  • nausea10,752
  • pain10,043
  • dyspnoea9,795
  • diarrhoea9,645
  • drug ineffective9,026
  • headache8,494
  • off label use8,237
  • end stage renal disease7,567

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,678
20052,531
20062,945
20072,610
20082,828
20093,147
20103,759
20113,563
20124,313
20133,291
20143,732
20155,932
20165,965
20175,590
201818,754
201916,519
20207,908
20218,696
202210,518
20238,441
20249,868
202510,012
20267,415

Recalls

1 FDA enforcement reports for this application.

  • Nov 22, 2016 · Class III · Terminated

    Subpotent Drug: Out of Specification (OOS) for potency at the 6-month stability time point.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Protonix IV (Pantoprazole Sodium)

2024 spending

$30K

Beneficiaries

42

346 claims

Per beneficiary

$707

$6.68 per unit

View as table
YearSpending
2020$41,138
2021$25,675
2022$27,564
2023$24,157
2024$29,677

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 616 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.